Cargando…

Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle

Ferumoxytol is an intravenous iron oxide nanoparticle formulation that has been approved by the U.S. Food and Drug Administration (FDA) for treating anemia in patients with chronic kidney disease. In recent years, ferumoxytol has also been demonstrated to have potential for many additional biomedica...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yue, Hsu, Jessica C., Koo, Hyun, Cormode, David P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692919/
https://www.ncbi.nlm.nih.gov/pubmed/34976214
http://dx.doi.org/10.7150/thno.67375
_version_ 1784619035707572224
author Huang, Yue
Hsu, Jessica C.
Koo, Hyun
Cormode, David P.
author_facet Huang, Yue
Hsu, Jessica C.
Koo, Hyun
Cormode, David P.
author_sort Huang, Yue
collection PubMed
description Ferumoxytol is an intravenous iron oxide nanoparticle formulation that has been approved by the U.S. Food and Drug Administration (FDA) for treating anemia in patients with chronic kidney disease. In recent years, ferumoxytol has also been demonstrated to have potential for many additional biomedical applications due to its excellent inherent physical properties, such as superparamagnetism, biocatalytic activity, and immunomodulatory behavior. With good safety and clearance profiles, ferumoxytol has been extensively utilized in both preclinical and clinical studies. Here, we first introduce the medical needs and the value of current iron oxide nanoparticle formulations in the market. We then focus on ferumoxytol nanoparticles and their physicochemical, diagnostic, and therapeutic properties. We include examples describing their use in various biomedical applications, including magnetic resonance imaging (MRI), multimodality imaging, iron deficiency treatment, immunotherapy, microbial biofilm treatment and drug delivery. Finally, we provide a brief conclusion and offer our perspectives on the current limitations and emerging applications of ferumoxytol in biomedicine. Overall, this review provides a comprehensive summary of the developments of ferumoxytol as an agent with diagnostic, therapeutic, and theranostic functionalities.
format Online
Article
Text
id pubmed-8692919
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-86929192022-01-01 Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle Huang, Yue Hsu, Jessica C. Koo, Hyun Cormode, David P. Theranostics Review Ferumoxytol is an intravenous iron oxide nanoparticle formulation that has been approved by the U.S. Food and Drug Administration (FDA) for treating anemia in patients with chronic kidney disease. In recent years, ferumoxytol has also been demonstrated to have potential for many additional biomedical applications due to its excellent inherent physical properties, such as superparamagnetism, biocatalytic activity, and immunomodulatory behavior. With good safety and clearance profiles, ferumoxytol has been extensively utilized in both preclinical and clinical studies. Here, we first introduce the medical needs and the value of current iron oxide nanoparticle formulations in the market. We then focus on ferumoxytol nanoparticles and their physicochemical, diagnostic, and therapeutic properties. We include examples describing their use in various biomedical applications, including magnetic resonance imaging (MRI), multimodality imaging, iron deficiency treatment, immunotherapy, microbial biofilm treatment and drug delivery. Finally, we provide a brief conclusion and offer our perspectives on the current limitations and emerging applications of ferumoxytol in biomedicine. Overall, this review provides a comprehensive summary of the developments of ferumoxytol as an agent with diagnostic, therapeutic, and theranostic functionalities. Ivyspring International Publisher 2022-01-01 /pmc/articles/PMC8692919/ /pubmed/34976214 http://dx.doi.org/10.7150/thno.67375 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Huang, Yue
Hsu, Jessica C.
Koo, Hyun
Cormode, David P.
Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
title Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
title_full Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
title_fullStr Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
title_full_unstemmed Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
title_short Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
title_sort repurposing ferumoxytol: diagnostic and therapeutic applications of an fda-approved nanoparticle
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692919/
https://www.ncbi.nlm.nih.gov/pubmed/34976214
http://dx.doi.org/10.7150/thno.67375
work_keys_str_mv AT huangyue repurposingferumoxytoldiagnosticandtherapeuticapplicationsofanfdaapprovednanoparticle
AT hsujessicac repurposingferumoxytoldiagnosticandtherapeuticapplicationsofanfdaapprovednanoparticle
AT koohyun repurposingferumoxytoldiagnosticandtherapeuticapplicationsofanfdaapprovednanoparticle
AT cormodedavidp repurposingferumoxytoldiagnosticandtherapeuticapplicationsofanfdaapprovednanoparticle